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Objective: Chemoradiation followed by resection has been studied with increasing interest. Recent publications
have stressed the negative side effects of this approach when associated with a pneumonectomy. Right-sided
pneumonectomy is associated with a prohibitive mortality rate after preoperative chemoradiation. The article
by Boffa and colleagues proposes that this procedure can be performed with relative safety.
Methods: A review of the English literature over 5 years was undertaken to identify articles and presentations
involving pneumonectomy after preoperative chemoradiation with curative intent.
Results: Eleven articles reporting results of chemoradiation followed by surgery are reviewed with attention
particularly made to results of pneumonectomy. The data from these articles, including morbidity and mortality,
are presented. This counterpoint purports to describe the current state of the literature surveyed related to pneu-
monectomy after chemoradiation.
Conclusion: The majority of articles reviewed stress the high risks of morbidity and mortality with pneumonec-
tomy after chemoradiation. Although some centers still routinely perform this approach, results from prospec-
tively collected data in a careful trial setting are needed to validate this approach. Until then, pneumonectomy
after chemoradiation should be used with caution in experienced centers.Chemoradiation therapy (CRT) followed by resection has
been studied with increasing interest in the United States
and abroad. Recent publications have stressed the negative
side effects of this approachwhen associated with a pneumo-
nectomy. Specifically, there are numerous studies showing,
in particular, that right-sided pneumonectomy is associated
with a prohibitive mortality rate after preoperative CRT.
This has led some authors to advocate chemotherapy induc-
tion alone followed by resection or even deny potentially cu-
rative resection in these patients when a pneumonectomy is
indicated. The presentation by Boffa and colleagues1 pro-
poses that this procedure can be performed with relative
safety. I have been given the assignment to challenge Boffa
and colleagues’ proposal that pneumonectomy after neoad-
juvant CRT is safe. This counterpoint purports to describe
the current state of the literature surveyed related to pneumo-
nectomy after CRT.
MATERIALS AND METHODS
A review of the English literature over the last 5 years was undertaken to
identify articles and presentations involving pneumonectomy after preopera-
tive CRT with curative intent. Only articles that discussed separate results of
pneumonectomy were included. Key words included pneumonectomy,
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cancer, and induction therapy. Case reports were not included in the review.
RESULTS
Eleven abstracts and articles were identified in addition to
the article presented by Boffa and colleagues.1 The role of
muscle flap in preventing early and late stump insufficiency
was analyzed in patients who underwent extrapleural pneu-
monectomy for malignant pleural mesothelioma in a series
by Beshay and colleagues.2 Thirty patients suitable for sur-
gery underwent neoadjuvant chemotherapy using cisplatin
and gemcitabine, followed by extrapleural pneumonectomy
and 54 Gy of radiotherapy (XRT); 88% of the patients were
male with a median age of 65 years. Extrapleural pneumo-
nectomy with muscle flap was performed through an antero-
lateral thoracotomy. One patient (3%) died of pulmonary
embolism on postoperative day 2. Minor complications oc-
curred in the early postoperative phase in 8 patients (25%).
There was no early or late bronchial stump insufficiency dur-
ing the 15-month follow-up.2 Although this series did not
use radiation preoperatively, and all patients had mesotheli-
oma, this recent series shows that excellent surgical results
can be achieved even with all patients undergoing pneumo-
nectomy, chemotherapy, and radiation by frequent use of
muscle flaps.
Three-dimensional, conformal 4500 cGy XRT with con-
current chemotherapy using cisplatin 20 mg/m2 and etopo-
side 50 mg/m2 was applied to a group of patients with
stage IIIA non–small cell lung cancer (NSCLC) in a study
by Pourel and colleagues.3 Three to 4 weeks after CRT, pa-
tients were reassessed for surgical candidacy. Surgery wasCardiovascular Surgery c Volume 138, Number 2 295
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ceived an additional 20 to 25 Gy boost or 1 extra cycle of
cisplatinþetoposide. A total of 107 patients received induc-
tion CRT followed by surgery. There were 18 stage IIB-
Pancoast tumors, 58 IIIA tumors, and IIIB tumors found in
31 patients. Squamous cell carcinoma was found in 48%,
adenocarcinoma was found in 44%, and large-cell carci-
noma was found in 14% of patients. Seventy-two patients
(67%) underwent resection, including pneumonectomy in
21, lobectomy in 45, and bilobectomy in 5. Carcinoma
was found to be unresectable in 1 patient. Macroscopic
complete resection was achieved in all other patients. In
the 3-month postoperative period, 5 patients (6.9%) died, in-
cluding 4 patients after pneumonectomy (right in 3 patients,
left in 1 patient). A pathologic complete response or micro-
scopic residual foci were found in 39.5%. Two and 3-year
overall survivals were 55% and 40%, respectively, and
median survival times were 62% and 51%, respectively
(median ¼ 36.5 months) for 71 patients undergoing resec-
tion. Multivariate analysis demonstrated surgical resection
and tumor necrosis greater than 50% (or pathologic com-
plete response) were predictive factors of the risk of death
(hazard ratio ¼ 0.50 and 0.48, P ¼ .006 and .038, respec-
tively). The authors concluded that pneumonectomy carries
a high risk of postoperative death (particularly right pneu-
monectomy) after induction CRT.3
In a series from theBrigham andWomen’sHospital, pneu-
monectomywas performed in 73 patients after radiation (me-
dian dose 54 Gy); 69 patients (95%) received concurrent
CRT. The median age was 62 years; 43 patients (59%)
were male. Thirty-seven patients (51%) had stage IIIA
NSCLC, 27 patients (37%) had stage IIIB NSCLC, 6
patients (8.2%) had stage IIB NSCLC, and 4 patients
(5.4%) had stage IVNSCLC (with solitary brainmetastasis).
Forty-four patients (60%) received carboplatin and pacli-
taxel chemotherapy. Fifteen patients (21%) received cis-
platin and etoposide as induction. Forty-five patients
(62%) underwent left pneumonectomy, and 28 patients
underwent right pneumonectomy. One- and 2-year overall
survivals were 70% and 49%, respectively. The 30- and
100-day mortalities were 6% and 10%, respectively. Four
of 73 patients (6%) died of acute respiratory distress
syndrome. Nonfatal treatment-related morbidity was 11%.
Univariate analysis demonstrated that right-sided pneumo-
nectomy was associated with a higher risk of treatment-
related mortality (P¼ .099), although these authors continue
to use pneumonectomy in carefully screened patients.4
In a series of stage IIIA-N2NSCLCs, 71 patients (60male,
median age of 60 years) received a 2-drug platinum-based
regimen followed by XRT (20–40 Gy). There were 9 com-
plete and 27 partial responses. Surgery included lobectomy
(44%) and left (15.5%) and right (27%) pneumonectomies.
Operative mortality was 4.2%, and 21 patients (29%) had
postoperative complications. Median survival was 17296 The Journal of Thoracic and Cardiovascular Sumonths. Three and 5-year survivals were 24% and 13%, re-
spectively. Five-year survival was worse in patients with
postoperative complications. Multivariate analysis identified
male gender and postoperative persistent positive lymph no-
des (LNs) as significant predictors (P ¼ .002). The authors
concluded that pathologic response after CRT for patients
with stage IIIA-N2 NSCLC enables a better survival.5
In a series from Toronto, 40 patients with biopsy-proven
T1-3 N2 M0 NSCLC underwent induction CRT before sur-
gical intervention; 25% of patients had T1 tumors, 62.5% of
patients had T2 tumors, 7.5% of patients had T3 tumors, and
5% of patients had T4 tumors. Induction chemotherapy in-
cluded cisplatin 50 mg/m2 and etoposide 50 mg/m2. Patients
underwent concurrent daily external beam XRT to 45 Gy.
Lung resection was undertaken within 6 weeks of comple-
tion of CRT. Two further cycles of consolidation chemother-
apy were then given if tolerated. Overall and disease-free
median survivals were 40 and 37.1 months, respectively.
Overall and disease-free 3-year survivals were 51.7% and
52.3%, respectively. R0 resection was achieved in 92.5%
of patients. Operative mortality was 7.5% (0% for lobec-
tomy; 27% for pneumonectomy). All mortalities occurred
within the first 2 years of the experience. The authors con-
cluded that CRT before pulmonary resection in carefully
selected patients with surgically resectable stage IIIA (N2)
NSCLC can lead to improved overall and disease-free sur-
vival. Although pneumonectomy carried a higher risk of
postoperative complication, the authors found the learning
curve reasonable.6
In a series from Chicago, 26 patients with NSCLC with
N2 disease underwent preoperative concurrent platinum-
based chemoradiotherapy with a dose of 58 Gy. The mortal-
ity rate was 7.7% (2 patients). Three patients (11.5%) had
minor complications. Downstaging was demonstrated in
76.9% of patients. A pathologic complete response rate of
34.6%was found. Downstaging of mediastinal LNs was ob-
served in 20 of 26 patients. One- and 3-year survivals were
80.2% and 45.7%, respectively. One- and 3-year disease-
free survivals were 76.9% and 37.3%, respectively. For pa-
tients with mediastinal downstaging, disease-free survival
was 79.2% versus 0% (P ¼ .0001). Differences in XRT
dose (50–60 Gy) and chemotherapy regimens did not signif-
icantly affect pathologic downstaging rates, complete re-
sponse rates, disease-free survival, or survival.7
A total of 139 patients (100 male and 39 female) under-
went induction therapy and surgery for stage IIIA and IIIB
NSCLC in a study from Rome, Italy. The mean age was
58.4 7.7 years. A total of 109 patients received chemother-
apy (with cisplatin and gemcitabine); 30 patients received
chemoradiotherapy (XRT median dose 50 Gy). Complica-
tions developed in 49 patients (35%). These included
persistent air leakage (23%–30% of lobectomies), cardiac
complications, respiratory failure, and infections. Five pa-
tients (3.5%) died in the postoperative period. Five patientsrgery c August 2009
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Only pneumonectomy was associated with an increased
mortality risk with no differences between intra- and extrap-
ericardial dissection or right and left pneumonectomies. The
authors concluded that pneumonectomy is associated with
an increased risk of mortality and should be performed
only in carefully selected patients.8
A recent phase I/II trial (UMGCC 9953) was reported by
the author’s group in patients with stage IIIA/B NSCLCwho
underwent induction CRT followed by surgery and consol-
idation chemotherapy. In phase I, escalating doses of carbo-
platin and vinorelbine were used with concurrent 69.6 Gy
hyperfractionated XRT. In the phase II portion of the study,
identical XRT with chemotherapy at maximal toxic dose
from the phase I was used. Surgical resection was under-
taken if mediastinal nodal clearance was proven by repeat
mediastinoscopy, thoracoscopy, or thoracotomy. Consolida-
tion chemotherapy consisted of carboplatin/vinorelbine for 3
cycles followed by docetaxel for 3 cycles. Forty-seven pa-
tients were enrolled in the study. There were 5 T4 tumors,
18 N2 tumors, and 8 N3 tumors found in 31 patients. Pre-
treatment staging was IIIA in 33 patients and IIIB in 14 pa-
tients. There were 15 men and 32 women with a mean age of
56 years. Twenty-eight patients completed trimodality with
surgery, including 22 lobectomies, 4 pneumonectomies, and
1 wedge resection. The postoperative mortality and morbid-
ity were 0% and 36%, respectively. Complications included
2 minor and 1major (ventilator dependence). The pathologic
complete response rate was 28.6%. The median survival
time for the entire cohort (n¼ 47) was 29.6 months. The me-
dian survival time was 55.8 months for patients with medi-
astinal nodal clearance (n ¼ 28).9
Intergroup 0139 was a prospective trial designed to deter-
mine the benefit of surgical resection after CRT. Although
the overall survival was better for patients undergoing surgi-
cal resection and disease-free survival was improved, the
study was skewed by poor postoperative results in patients
undergoing pneumonectomy, with a 26% mortality in this
subgroup. In a recent reanalysis of these data, when patients
with pneumonectomy were excluded, the results were statis-
tically improved for patients undergoing lobectomy alone
after CRT.10
In a recent study by Gamliel and colleagues,11 28 patients
(8 female) with a mean age of 53.4 years underwent pneu-
monectomy after neoadjuvant CRT. The preoperative regi-
men included concurrent chemotherapy with platinum/
etoposide or carboplatin/paclitaxel with concurrent XRT to
61.2 Gy. The mean interval between XRT and resection
was 67.1 days. All but 1 patient had downstaging, and 15
of 28 patients (53%) had a pathologic complete response.
All patients were discharged alive from the hospital. The
mean length of stay was 8.6 days. There was 1 death within
30 days. There were 14 major complications, including 1 pa-
tient with esophageal stricture, 3 patients with vocal cordThe Journal of Thoracic and Cparalysis, 4 patients with postoperative respiratory distress,
2 patients with arrhythmias, 1 patient with upper-extremity
venous thrombosis, and 3 patients with bronchopleural fistu-
lae (1 fatal, 1 treated conservatively, and 1 muscle flap was
done as a reoperation).11
Currently, Radiation Therapy Oncology Group 0229 is
a phase II trial of concurrent chemotherapy and high-dose
XRT followed by surgery in stage III NSCLC.12 This study
allows patients to undergo curative resection after high-dose
CRT. Preliminary data on these 60 patients will be important
in the near future when they are reported.
The current study by Boffa and colleagues1 describes 232
patients who underwent pneumonectomy at Massachusetts
General Hospital over a period of 20 years. A total of 201
underwent a preoperative mediastinoscopy. Seventy-three
patients underwent combined modality treatment (CRT).
Fifty-nine patients had CRT preoperatively, 8 patients had
preoperative chemotherapy alone, 8 patients hadpreoperative
XRT, and 8 patients had remote XRT. The mean XRT dose
was 50 Gy. There were 112 right and 120 left pneumonecto-
mies. There were 21 carinal pneumonectomies (6 of whom
had CRT preoperatively). The bronchial stump was covered
with pericardial fat in 120 patients, and intercostal muscle
flaps were used in 64 patients. The overall 30- and 90-day
mortalities were 9% and 13.4%, respectively. The mortality
was 7.4% for patients after induction therapy and 10% for
those with no preoperative therapy. Patients with right pneu-
monectomies fared worse than patients with left pneumonec-
tomies, although this was not true for those patients who
underwent induction therapy. Morbidity included 12 bron-
chopleural fistulae (5%); 75% of these patients subsequently
died. Pulmonary edema was more common in patients who
underwent resection alone. Multivariate analysis demon-
strated that preoperative cardiac illness, forced expiratory
volume in 1 second less than 1 liter, steroid use, and increased
blood loss were poor prognosticators. Early extubation and
negative LN at resection were good prognosticators.
DISCUSSION
This counterpoint depicts the current state of the literature
on pneumonectomy after CRT. Although several large series
have been quoted, there are no level 1 data to support either
performing or not performing pneumonectomy in this set-
ting. With this in mind, all the experiences cited herein, as
well as those cited in the article by Boffa and colleagues,1
must be taken with a grain of salt. The main limitation of
the article by Boffa and colleagues is the retrospective nature
of the review. In addition, there are many subgroups that
were included that might be best left out of this study. If
we focus only on the subset of 59 patients who had CRT pre-
operatively, there still is an impressive result with only
a 7.4% mortality and low leak rate. These authors have
found that poor cardiac or pulmonary status, steroid use,
and blood loss are prognosticators of a bad outcome.ardiovascular Surgery c Volume 138, Number 2 297
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First Author Reference Chemotherapy Radiotherapy dose Morbidity Mortality
Beshay 2 Cis/gem 54 25% 3%
Pourel 3 Cis/eto 45 (4/21) 19%
Allen 4 Carbo/tax 54 11% 6%
Cis/eto
Barle’si 5 platinum 20–40 29% 4.2%
Uy 6 Cis/eto 45 27%
Shaikh 7 platinum 58 7.7%
Venuta 8 Cis/gem 50 35% 12.5%
Edelman 9 Carb/vinor 69.6 36% 0%
Albain 10 Cis/eto 45 25% 26%
Gamliel 11 Cis/eto 61.2 50% 3.5%
Carbo/taxol
Boffa 1 Platinum 50 25% 9%The role of pneumonectomy after CRT is an important
topic of study as more patients are being offered aggressive
therapy for stage IIIA and IIIB disease. Since the Intergroup
trial demonstrated a mortality of 26% in a prospective, ran-
domized study, use of pneumonectomy in this setting has
faced significant criticism.10
The studies cited in this article report a mortality from 3%
to 27% for pneumonectomy after CRT (Table 1). Several
single institution studies, including recent studies reviewed
in this article, suggest a mortality not nearly as high as that
found in the Intergroup trial. The current article by Boffa
and colleagues1 reports a mortality ranging from 7% to
13.4% depending on whether induction therapy and right
or left pneumonectomy was performed. Additional criticism
is that most analyses do not include all patients seen at the
institution as an intent-to-treat analysis; that is, the overall
number of patients with IIIA or IIIB disease is generally
not available to the reader. One must assume that there are
other patients who underwent induction chemotherapy or
even combination CRT who did not go on to surgery. These
patients were generally excluded from surgery because of
progression of disease, lack of mediastinal nodal steriliza-
tion, or deterioration in their medical condition. This denom-
inator, if available, would help the analysis of many of these
articles. The only true prospective data analysis remains the
Intergroup study, which included a lower radiation dose and
was performed at a number of centers, probably reflecting
a ‘‘real life’’ mortality when this procedure is offered at in-
stitutions that are perhaps not considered ‘‘centers of excel-
lence’’ for this kind of surgery.
One of the main limitations in the current study, as well as
the many other single institution or phase 2 trials, is the lack
of standardization in staging and restaging. If all patients un-
dergo pretreatment positron emission tomography scanning
and pathologic LN sampling, the denominator would then
clearly be patients with proven pathologic N2/N3 disease.
In addition, these patients would then be stratified to bulky
versus nonbulky disease, microscopic versus macroscopic,298 The Journal of Thoracic and Cardiovascular Suand even single-station versus multiple-station disease.
Each of these subgroups might have different survivals if
clearly evaluated prospectively. Finally, restaging using
positron emission tomography/computed tomography fol-
lowed by pathologic staging using needle biopsy, mediasti-
noscopy, repeat mediastinoscopy, or video-assisted thoracic
surgery would further refine which patients then go on to
resection and appropriately identify subsets of patients
who are pathologic responders from those who are nonre-
sponders. Again, it is likely that survival would be correlated
to these findings. Lacking this type of specific staging data,
we are left to rely on previous studies that did identify sub-
groups of survivors and assume that we can extrapolate
those data to these studies.
Surgical considerations when offering pneumonectomy
after CRT include coverage of all bronchial stumps with
muscle flaps. Serratus anterior flaps are generally used by
our group for pneumonectomies, and intercostal muscle
flaps are used for lobectomies. Limited intraoperative fluid
administration is allowed in an attempt to minimize acute re-
spiratory distress syndrome. Barotrauma to the contralateral
lung is limited during single-lung ventilation by limiting
peak airway pressures and ventilatory volume. Also, every
attempt is made to achieve early extubation after the comple-
tion of the resection.
CONCLUSIONS
On the basis of the review of these recent studies, it would
seem that although there may be a benefit to lung resection
after CRT, themorbidity andmortality of performing a pneu-
monectomy are prohibitive. Unless specific subsets of pa-
tients can be identified, such as those with pathologic LN
response or with limited or no comorbidity, this extensive
surgery should be used cautiously or perhaps only in the
context of a clinical prospective trial.
Despite the data presented in this counterpoint, I believe
that Boffa and colleagues1 are correct in their conclusion.
Selected patients, especially those who are LN negative afterrgery c August 2009
Krasna Point/Counterpointpreoperative CRT, who are otherwise fit, relatively young,
with few if any cardiac risk factors for right- or left-sided
heart failure, should be offered a pneumonectomy for defin-
itive therapy. I agree that even a right pneumonectomy can
be performed safely with acceptably lowmorbidity and mor-
tality in selected patients at selected centers. This approach
requires an audacious surgical team, with technical experi-
ence to gain easy proximal control of fragile intrapericardial
arteries and veins, the potential for bypass backup, and an
ability to rotate multiple, complex muscle flaps at the time
of the first surgery. Although this may not be doable in all
centers, those who have significant experience should be en-
couraged to continue to offer this lifesaving option for these
patients with an otherwise fatal disease.
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